Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Nauseef, Jones T.
Thomas, Charlene
Ho, Benedict
Zuloaga, Juana Martinez
Gonzalez, Brian D.
Sun, Michael
Sartor, A. Oliver
Singh, Sharon
Bissassar, Mahelia
Fernandez, Escarleth
Tan, Angela
Patel, Amie
Naiz, Muhammad Obaid
Vallabhajosula, Shankar
Molina, Ana M.
Sternberg, Cora N.
Nanus, David M.
Osborne, Joseph
Bander, Neil Harrison
Tagawa, Scott T.
机构：
[1] New York Presbyterian Hosp, Weill Cornell Med Ctr, New York, NY USA
[2] Weill Cornell Med, New York, NY USA
[3] Cornell Univ, Ithaca, NY USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Tulane Med Sch, Sch Med, New Orleans, LA USA
[6] Weill Cornell Med Ctr, New York, NY USA
[7] Weill Cornell Med, Englander Inst Precis Med, Hematol Oncol, New York, NY USA
[8] Sandra & Edward Meyer Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.077
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
77
引用
收藏
页数：3
相关论文
共 50 条
  • [31] 225Ac-PSMA / 177Lu-PSMA Tandem Therapy for Metastatic Castration-Resistant Prostate Cancer (a)over-cap(sic)" A Prospective Phase 3 Randomized Study from Azerbaijan
    Novruzov, Fuad
    Mehdi, Elnur
    Shukurov, Razim
    Dadashov, Zamil
    Guliyev, Fuad
    Musayev, Teymur
    Paez, Diana
    Aliyev, Altay
    Giammarile, Francesco
    Aliyev, Jamil
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [32] Initial results from AQUARiUS, a prospective, observational, multi-centre phase IV study assessing patient-reported outcomes (PROs) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate plus prednisone (AAP) or enzalutamide (ENZ)
    Thiery-Vuillemin, A.
    Poulsen, M. H.
    Reid, A.
    Lagneau, E.
    Ploussard, G.
    Birtle, A.
    Dourthe, L. M.
    Beal-Ardisson, D.
    Pintus, E.
    Trepiakas, R.
    Lukac, M.
    Van Sanden, S.
    Dearden, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study
    Sanjana Ballal
    Madhav P Yadav
    Swayamjeet Satapathy
    Shobhana Raju
    Madhavi Tripathi
    Nishikant A Damle
    Ranjit K Sahoo
    Chandrasekhar Bal
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 3777 - 3789
  • [34] Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study
    Ballal, Sanjana
    Yadav, Madhav P.
    Satapathy, Swayamjeet
    Raju, Shobhana
    Tripathi, Madhavi
    Damle, Nishikant A.
    Sahoo, Ranjit K.
    Bal, Chandrasekhar
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (12) : 3777 - 3789
  • [35] Patient reported outcomes (PROs) among patients with metastatic castration-resistant prostate cancer (mCRPC) by homologous recombination repair mutations (HRRm) gene clusters: Findings from the phase 3 TALAPRO-2 study cohort 2.
    Fizazi, Karim
    Shore, Neal D.
    Fong, Peter C. C.
    Azad, Arun
    Matsubara, Nobuaki
    Saad, Fred
    De Giorgi, Ugo
    Joung, Jae Young
    Jones, Robert J.
    Zschaebitz, Stefanie
    Oldenburg, Jan
    Dunshee, Curtis
    Carles, Joan
    Fay, Andre P.
    Cislo, Paul
    Kirker, Melissa
    Healy, Cynthia G.
    Niyazov, Alexander
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 109 - 109
  • [36] Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (Pts).
    Fizazi, Karim
    Chi, Kim N.
    De Bono, Johann Sebastian
    Gomella, Leonard G.
    Miller, Kurt
    Rathkopf, Dana E.
    Ryan, Charles J.
    Scher, Howard I.
    Shore, Neal D.
    De Porre, Peter
    Londhe, Anil
    McGowan, Tracy
    Pehlivanov, Nonko
    Charnas, Robert Louis
    Todd, Mary Beth
    Montgomery, Robert B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [37] ASSESSMENT OF CORTICOSTEROID (CS)-ASSOCIATED ADVERSE EVENTS (AES) WITH LONG-TERM (LT) EXPOSURE TO LOW-DOSE PREDNISONE (P) GIVEN WITH ABIRATERONE ACETATE (AA) TO METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS)
    Gomella, Leonard G.
    Chi, Kim N.
    de Bono, Johann S.
    Fizazi, Karim
    Miller, Kurt
    Rathkopf, Dana E.
    Ryan, Charles J.
    Scher, Howard I.
    Shore, Neal D.
    De Porre, Peter
    Londhe, Anil
    McGowan, Tracy
    Pelhivanov, Nonko
    Charnas, Robert
    Todd, Mary B.
    Montgomery, Bruce
    JOURNAL OF UROLOGY, 2015, 193 (04): : E1091 - E1091
  • [38] SatisfACtion: a phase 1/2 study of [225Ac]Ac-PSMA-R2 in patients with PSMA-positive metastatic castration-resistant prostate cancer with or without previous [177Lu]Lu-PSMA radioligand therapy
    Kraeber-Bodere, F.
    Mahammedi, H.
    Giraudet, A.
    Wehbe, J.
    Wilke, C.
    Olivier, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S280 - S280
  • [39] Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Markowski, Mark Christopher
    Kilari, Deepak
    Eisenberger, Mario A.
    Mckay, Rana R.
    Dreicer, Robert
    Trikha, Mohit
    Heath, Elisabeth I.
    Li, Jing
    Garzone, Pamela D.
    Young, Travis S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA: Results from a phase III (TALAPRO-2) study
    Fay, A. P.
    Fizazi, K.
    Matsubara, N.
    Azad, A. A.
    Saad, F.
    De Giorgi, U. F. F.
    Joung, J. Y.
    Fong, P. C.
    Jones, R. J.
    Zschaebitz, S.
    Oldenburg, J.
    Shore, N. D.
    Dunshee, C.
    Galceran, J. Carles
    Cislo, P.
    Chang, J.
    Healy, C. G.
    Niyazov, A.
    Agarwal, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S980 - S981
12345